Table Graph
      published meta-analysis   sensitivity analysis   studies

placebo in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias Emergency room visit or hospitalizationdetailed resultsCov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 (REV) 8.05 [0.42; 152.50] 8.05[0.42; 152.50]Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 (REV)10%1,505NAnot evaluable deathsdetailed resultsCov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 (REV) 1.00 [0.14; 7.14] 1.00[0.14; 7.14]Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 (REV)10%2,617NAnot evaluable symptomatic Covid-19detailed resultsCov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 (REV) 5.74 [2.99; 11.02] 5.74[2.99; 11.02]Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 (REV)10%1,505NAnot evaluable serious adverse eventsdetailed resultsCov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 (REV) 0.34 [0.20; 0.57] 0.34[0.20; 0.57]Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 (REV)10%2,617NAnot evaluable adverse eventsdetailed resultsCov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 (REV) 1.61 [1.35; 1.93] 1.61[1.35; 1.93]Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 (REV)10%2,617NAnot evaluable0.220.01.0relative treatment effectwww.metaEvidence.org2024-06-06 13:15 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 650 - roots T: 650

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons